SEC Tracker
Get the app
LUNG · XBRL financial data

Pulmonx financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (LUNG's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers19,278*18,85420,78320,38723,765*22,53823,85921,50222,598*20,58622,75622,835
Cost of goods and services sold4,878*4,7765,4765,3616,175*6,1966,6555,4505,057*4,5425,0145,436
Gross profit14,400*14,07815,30715,02617,590*16,34217,20416,05217,541*16,04417,74217,399
Research and development3,896*4,2105,6153,7444,001*4,7565,3064,8464,583*4,8995,0344,864
Selling, general and administrative24,423*24,40425,31425,41127,006*26,14926,70225,59922,861*24,10121,76520,025
Total operating expenses28,319*28,61430,92929,15531,007*30,90532,00830,44527,444*29,00026,79924,889
Operating income (loss)(13,919)*(14,536)(15,622)(14,129)(13,417)*(14,563)(14,804)(14,393)(9,903)*(12,956)(9,057)(7,490)
Interest income1,541*1,4411,3061,2691,045*864723611453*350329345
Interest expense905*883891891842*781799805770*9761,2181,234
Other income (expense)(357)*415(35)(201)77*167(116)758(19)*77(1)136
Income tax expense (benefit)248*1868419238*135177128186*149133151
Net income (loss)(13,888)*(13,749)(15,326)(14,144)(13,175)*(14,448)(15,173)(13,957)(10,425)*(13,654)(10,080)(8,394)
Earnings per share, basic USD per share(0.36)*(0.36)(0.39)(0.36)(0.33)*(0.36)(0.38)(0.34)(0.25)*(0.33)(0.24)(0.19)
Earnings per share, diluted USD per share(0.36)*(0.36)(0.39)(0.36)(0.33)*(0.36)(0.38)(0.34)(0.25)*(0.33)(0.24)(0.19)
Weighted average shares, basic thousands of shares38,377*38,63638,94339,27639,582*39,95540,43040,93741,404*41,89842,46943,177
Weighted average shares, diluted thousands of shares38,377*38,63638,94339,27639,582*39,95540,43040,93741,404*41,89842,46943,177

Balance sheet

CSV

Fiscal quarters (LUNG's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents83,54770,15863,46463,31270,90574,55575,46676,54969,75161,57255,84352,690
Accounts receivable12,10510,52211,08011,67013,12013,97515,90313,79712,07210,83012,24712,014
Inventory16,74317,22816,98016,95916,91516,80916,17516,24815,84516,31016,39015,436
Prepaid and other current assets4,2353,8193,2974,2634,4744,1963,4584,3803,7583,7773,3943,664
Total current assets150,422147,936146,159140,929136,248123,939120,020111,235101,68492,74688,13384,061
Property and equipment, net4,0284,2182,8302,9832,9072,8262,6602,4432,2202,0601,8851,761
Right-of-use asset3,4062,70518,49018,23618,54518,68218,64318,27918,02817,65417,26717,039
Goodwill2,3332,3332,3332,3332,3332,3332,3332,3332,3332,3332,3332,333
Total assets177,781164,584172,627167,401162,850150,736147,187138,281129,291119,966114,732110,212
Accounts payable1,4973,1253,1814,5763,8274,2806,5576,4203,9053,4744,6754,512
Accrued liabilities16,23410,07111,78312,77916,47211,54714,38814,93614,55613,72814,07014,555
Total current liabilities23,15721,29416,30118,30024,43724,94522,44722,87820,05818,90620,40520,739
Long-term debt35,08932,00237,11037,13734,00229,39337,01137,02536,98937,20937,42837,712
Lease liability, non-current1,10665017,91417,91018,51518,65218,59818,29818,05917,74117,40317,145
Total liabilities59,46654,08671,44373,47677,04173,06978,09778,24875,17574,20575,53676,012
Accumulated deficit(411,161)(424,910)(440,236)(454,380)(467,555)(482,003)(497,176)(511,133)(521,558)(535,212)(545,292)(553,686)
Total stockholders' equity118,315110,498101,18493,92585,80977,66769,09060,03354,11645,76139,19634,200
Total liabilities and equity177,781164,584172,627167,401162,850150,736147,187138,281129,291119,966114,732110,212
Common shares outstanding (cover page) thousands of shares38,53738,81639,15339,48839,79640,25840,74741,24742,23742,23742,94843,551

Cash flows

CSV

Fiscal quarters (LUNG's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(13,888)*(13,749)(15,326)(14,144)(13,175)*(14,448)(15,173)(13,957)(10,425)*(13,654)(10,080)(8,394)
Stock-based compensation5,598*5,6735,920*5,839*5,523*5,6126,214*5,166*4,241*4,1363,698*3,611*
Net cash from operating activities(8,449)*(11,795)(5,770)*(7,242)*(6,730)*(13,222)(3,908)*(8,162)*(7,084)*(10,097)(5,214)*(3,183)*
Purchases of property and equipment200*451469*416*111*30149*89*13*91*8*
Net cash from investing activities(2,755)*(2,507)(835)*6,751*14,067*16,3135,471*8,711*(13)*(9)(1)*(8)*
Share repurchasesyear only———————————
Proceeds from long-term debt0*00*0*0*———————
Net cash from financing activities17*864(22)*459*62*664(67)*181*55*2,026(513)*161*
Net change in cash(11,397)*(13,390)(6,673)*(151)*7,592*3,650913*1,085*(6,801)*(8,180)(5,727)*(3,155)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Pulmonx52,69022,835(3,183)*43.6M8.5 quarters 10-QSep 30, 2026
Microbot Medical3,152241(4,989)*67.2M13.5 quarters 10-QJun 30, 2026
TriSalus Life Sciences46,28811,407(10,129)*61.6M4.6 quarters 10-QJun 30, 2026
Fonar53,65026,4721,580*not reported— 10-QMar 31, 2026
CVRx64,58615,705(8,826)*26.6M7.3 quarters 10-QJun 30, 2026
LENSAR13,56516,495(127)*12.3M106.8 quarters 10-QJun 30, 2026
Accuray40,623100,919*2,427*119.4M— 10-KJun 30, 2026
KORU Medical Systems8,28812,045216*46.2M— 10-QJun 30, 2026
Carlsmed46,244not reported(7,358)*27.3M9.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.